Add-On Nuplazid Gets a Win in Early Schizophrenia Trial

(MedPage Today) -- Adjunctive treatment with the atypical antipsychotic pimavanserin (Nuplazid) succeeded in treating negative symptoms of schizophrenia, according to the ADVANCE study.
In the 26-week phase II study, people on pimavanserin added...